Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 7/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14053968 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL27272428 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL17031906 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL1336739 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL3050914 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL8337646 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL4840543 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL4847115 | 1.00 | CHRM2 (0.45) | CHRM2CHRM1CHRM3ACEPREP | |
| SCHEMBL14865498 | 0.99 | CHRM2 (0.44) | CHRM2CHRM1CHRM3ACEPREP | |
| Cesium SCHEMBL8725844 | 0.99 | CHRM2 (0.44) | CHRM2CHRM1CHRM3ACEPREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-9421192-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227961-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| CN-104447707-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-08 | — | — | US | disclosed |
| CN-101558059-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-12-03 | — | — | CN | disclosed |
| US-8900566-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20060178383-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-10 | — | — | US | disclosed |
| US-20060079686-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2006-04-13 | — | — | US | disclosed |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
| WO-2006024932-A1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006017844-A1 | NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005028502-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | CHRM2 2236/4885CHRM1 1416/4885CHRM3 2033/4885 |
| US-20160067223-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885 |
| US-20060178383-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | CHRM2 3172/4885CHRM1 3311/4885CHRM3 3019/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | CHRM2 2195/4885CHRM1 1403/4885CHRM3 2018/4885 |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | CHRM2 3172/4885CHRM1 3311/4885CHRM3 3019/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885 |
| US-20060079686-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | CHRM2 3172/4885CHRM1 3311/4885CHRM3 3019/4885 |
| US-20150011754-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.